B AC K G R O U N D Our objective was to reveal whether or not protective amount of rapid antibody titer could be produced with an accelerated vaccination regime with three different Hepatitis B virus (H B V) vaccine. M ET H O D S The 180 male volunteer soldiers were enrolled into study. Three doses of vacc ine each cont a ining 20 micrograms of rec o mbinant HBsAg from three diff erent company; [GenH evac B (Pasteur- Mer i eux, France), Eng erix B (GSK, Belg ium), and Hep avax Gene (Kor ean G r een Cross Corp or at ion, Kor ea)] were adm in i st ered to the delt oid muscles on days 0, 7 and 21. R E S U LT S After three doses of vaccination, Anti-HBs titers had reached protective levels in all groups. The percent age of vaccines with seroprotective levels of Anti HBs (≥10 mIU/ ml) on day 30 was 70, 87.5 and 80% in groups of GenH evac, E ng erix B and Hep avax Gene, resp e ct ively. Acc el erated vaccinat ion with vaccines produced via recombinant gene technology from three different comm e rcial company was found to be safe and relatively immunog enic. Anti-HBs titers in three different vaccine group were similar to each o ther. There was no diff er e nce of ser o pr ot e ct ion rate (73.5-80%) at the end of 12 months and the three week accel er ated vaccin at ion prov ided prot e ctive antibody titers. CO N C L U S I O N S In order to provide rapid antibody production against HBV, the accelerated vaccination programme was stated to be a better option especially in a limited time periods.